Who is sponsoring NCT07115095?

NCT07115095 is sponsored by Nanlin Li.

What drugs are being tested in NCT07115095?

Interventions in NCT07115095: TP Chemotherapy + Trastuzumab + Pertuzumab, TP Chemotherapy + Trastuzumab.

What condition does NCT07115095 study?

NCT07115095 studies HER2-positive Breast Cancer.

Is NCT07115095 still recruiting?

NCT07115095 is currently completed. Last updated 11 August 2025.

Last reviewed 2025-08-11 · How we verify

NCT07115095

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer

Completed NA Last updated 11 August 2025

What this trial tests

NA trial testing TP Chemotherapy + Trastuzumab + Pertuzumab in HER2-positive Breast Cancer in 98 participants. Completed in 1 January 2023.

Timeline

1 January 2021

Primary endpoint
1 January 2023

1 January 2023

Quick facts

Lead sponsor	Nanlin Li
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	98
Start date	1 January 2021
Primary completion	1 January 2023
Estimated completion	1 January 2023
Sites	1 location across China

Drugs / interventions tested

TP Chemotherapy + Trastuzumab + Pertuzumab — full drug profile →
TP Chemotherapy + Trastuzumab — full drug profile →

Conditions studied

HER2-positive Breast Cancer — all drugs for HER2-positive Breast Cancer →

Sponsor

Nanlin Li — full company profile →

Who can join

18 and older, female only, with HER2-positive Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, randomized study to compare the efficacy of TP (Taxane plus Carboplatin) chemotherapy combined with dual-HER2 blockade (trastuzumab and pertuzumab) versus TP chemotherapy plus single-HER2 blockade (trastuzumab) in patients with HER2-positive breast cancer. The study aims to evaluate treatment response and the clinical value of serum tumor markers (CEA, CA125, and CA153) in assessing therapeutic efficacy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for HER2-positive Breast Cancer

Currently open trials in the same condition.

NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
NCT07377643 — IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer · Phase 3 · recruiting
NCT07510802 — Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC · Phase 1, PHASE2 · recruiting
NCT07486089 — Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) · Phase 1, PHASE2 · recruiting
NCT07102381 — A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Ca · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07115095 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanlin Li
Last refreshed: 11 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07115095.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing